<DOC>
	<DOCNO>NCT02174549</DOCNO>
	<brief_summary>This phase 1 study determine optimal dose tolerability hypoxia-activating agent , tirapazamine , combine embolization liver cancer . Liver cancer patient Child-Pugh score A , suitable embolization tumor 4 nodule eligible . Tirapazamine give intravenous infusion first two cohort switch intra-arterial injection embolization subsequent cohort . Treatment effect evaluate MRI base modify RECIST criterion . Repeat treatment necessary disease progression . Each patient allow 6 treatment 18-month period .</brief_summary>
	<brief_title>Dose-defining Study Tirapazamine Combined With Embolization Liver Cancer</brief_title>
	<detailed_description>The study 3+3 design dose escalation . Each cohort 3-6 patient base tolerability . Patients receive escalate dos tirapazamine maximally tolerate dose . Embolization perform per standard practice use Lipiodol Gelfoam X-ray guidance . Once suitable dose determine , expansion cohort 15 patient treat recommend phase 2 dose determine preliminary efficacy . Depending dose escalation , 23-63 patient enrol study . All patient admit hospital day embolization , post-treatment observation do hospital liver function test show improvement discharge hospital . Adverse event evaluate CTCAE vs. 4.0 efficacy evaluate MRI use modify RECIST criterion .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Tirapazamine</mesh_term>
	<criteria>Confirmed diagnosis HCC &gt; 10 mm characteristic 4phase CT dynamic contrast enhance MRI find show intense arterial uptake follow `` washout '' contrast venousdelayed phase per American Association Study Liver Disease ( AASLD ) criterion . Patients age 20 75 Patients single multiple ( 24 nodule ) HCC unsuitable unwilling surgical resection RFA . The large tumor nodule le 10 cm large diameter . The total volume tumor exceed 50 % liver Patients candidate TAE Transarterial ChemoEmbolization ( TACE ) . No tumor invasion portal vein thrombosis portal vein . Patients lymph node involvement distant metastasis . ECOG score 01 known cardiac , pulmonary renal dysfunction ChildPugh score group A liver functional score Patients measurable disease contrast MRI . Prior local therapy surgical resection , radiofrequency ablation , alcohol injection allow long tumor progress prior treatment patient still candidate TAE . All prior therapy must least 4 week prior enrollment free treatmentrelated toxicity . Patients normal organ function : ANC ≥ 1500 /µL , Hemoglobin ≥ 9 gm/dL , Platelets ≥ 75,000 /µL , Creatinine ≤ 2 mg/dL , AST ALT &lt; 5 X upper normal limit current institution ; bilirubin &lt; 2.0 mg/dL , PT prolongation 4 sec upper limit normal Patients able understand willing sign inform consent . Men woman childbearing age need commit use two method contraception simultaneously avoid pregnancy . Patients liver transplantation Patients HCC lesion whose feed artery identify arteriogram injection study medication exclude embolization procedure . Patients major medical problem cardiac , pulmonary ( COPD require constant oxygen ) , renal ( creatinine 2.0 ) disease , active infectious disease ( except chronic Hepatitis B C ) , nonhealing ulceration Patients uncontrolled hepatitis B C high viral DAN RNA titer 3 X ULN treat enrolled study . Patients HBV HCV medication enrollment study hold medication Day 1 resume prior medication day 2 . Patients clinical evidence hypoxia O2 saturation le 92 % without oxygen . Patients evidence arterial insufficiency microangiopathy organ due reason , diabetes , could lead distal extremity hypoxia , evidence gangrenous change distal limbs require resection reason . Patients interferon treatment , eligible washout period 4 week . Patients know HIV infection Patients major gastrointestinal bleeding prior 2 month enrollment . Patient chronic anticoagulation therapy consider risk invasive procedure TAE . Patients know diagnosis cancer HCC , unless cancer consider cure treat physician due evidence recurrence 5 year , localize resected earlystage cancer basal cell carcinoma , resect early stage prostate cancer , superficial melanoma , breast ductal carcinoma situ , without evidence recurrence year . The impact tirapazamine pregnant lactate woman investigate . Patients pregnant lactate allow study Patients QTc interval &gt; 470 msec know congenital long QTc syndrome . Patients take medication know prolong QT interval and/or associate risk Torsades de Pointes within 7 day prior first dose . Patients antiplatelet agent aspirin , nonsteroidal antiinflammatory drug ( NSAIDs ) platelet inhibitor clopidogrel , vorapaxar , dipyridamole need washout period 7 day embolization .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hypoxia</keyword>
	<keyword>Embolization</keyword>
	<keyword>Tirapazamine</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
</DOC>